Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma
- Status
- COMPLETED
- Phase
- PHASE2
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Pembrolizumab for Locally Advanced, Irresectable, Non-metastatic dMMR Colorectal Cancers
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of NDI 1150-101 in Patients With Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy
- Status
- COMPLETED
- Phase
- PHASE2
A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3